A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema
Latest Information Update: 02 Jul 2025
At a glance
- Drugs Tivozanib (Primary) ; Aflibercept
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors Kyowa Kirin
Most Recent Events
- 05 Jun 2025 Planned End Date changed from 1 Dec 2025 to 30 Sep 2026.
- 05 Jun 2025 Planned primary completion date changed from 1 Nov 2025 to 31 Aug 2026.
- 06 Feb 2024 Status changed to recruiting, according to a Kyowa Kirin Co. media release.